NO20065052L - Krystallinsk polymorf av et bazedoksifenacetat - Google Patents

Krystallinsk polymorf av et bazedoksifenacetat

Info

Publication number
NO20065052L
NO20065052L NO20065052A NO20065052A NO20065052L NO 20065052 L NO20065052 L NO 20065052L NO 20065052 A NO20065052 A NO 20065052A NO 20065052 A NO20065052 A NO 20065052A NO 20065052 L NO20065052 L NO 20065052L
Authority
NO
Norway
Prior art keywords
crystalline polymorph
bazedoxifene acetate
bazedoxifene
acetate
polymorph
Prior art date
Application number
NO20065052A
Other languages
English (en)
Norwegian (no)
Inventor
Kadum Abdul Nabi Ali
Silvio Iera
Christopher Demerson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065052(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20065052L publication Critical patent/NO20065052L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20065052A 2004-04-07 2006-11-02 Krystallinsk polymorf av et bazedoksifenacetat NO20065052L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56058204P 2004-04-07 2004-04-07
US66017805P 2005-03-10 2005-03-10
PCT/US2005/011724 WO2005100316A1 (en) 2004-04-07 2005-04-06 Crystalline polymorph of a bazedoxifene acetate

Publications (1)

Publication Number Publication Date
NO20065052L true NO20065052L (no) 2006-11-06

Family

ID=34966308

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065052A NO20065052L (no) 2004-04-07 2006-11-02 Krystallinsk polymorf av et bazedoksifenacetat

Country Status (18)

Country Link
US (1) US7683051B2 (https=)
EP (1) EP1732890A1 (https=)
JP (2) JP2007532560A (https=)
KR (1) KR20060135866A (https=)
AR (1) AR048527A1 (https=)
AU (1) AU2005233133A1 (https=)
BR (1) BRPI0509191A (https=)
CA (1) CA2561010A1 (https=)
CR (1) CR8615A (https=)
EC (1) ECSP066911A (https=)
IL (1) IL178236A0 (https=)
NO (1) NO20065052L (https=)
PA (1) PA8629101A1 (https=)
PE (1) PE20060676A1 (https=)
RU (1) RU2006132180A (https=)
SG (1) SG151331A1 (https=)
TW (1) TWI346105B (https=)
WO (1) WO2005100316A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532548A (ja) 2004-04-07 2007-11-15 ワイス バゼドキシフェンアセテートの結晶質多形体
WO2005100316A1 (en) 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of a bazedoxifene acetate
US8538393B1 (en) 2004-09-21 2013-09-17 Advanced Ground Information Systems, Inc. Method to provide ad hoc and password protected digital and voice networks
US10645562B2 (en) 2004-09-21 2020-05-05 Agis Software Development Llc Method to provide ad hoc and password protected digital and voice networks
WO2007002823A2 (en) * 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
JP2009506053A (ja) 2005-08-24 2009-02-12 ワイス 酢酸バゼドキシフェン製剤
PE20090100A1 (es) * 2007-03-30 2009-02-26 Wyeth Corp Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas
CZ302358B6 (cs) 2007-07-25 2011-03-30 Zentiva, A. S. Nové soli bazedoxifenu
US20100016290A1 (en) * 2008-02-11 2010-01-21 Livius Cotarca Amorphous polymorph of bazedoxifene acetate
ES2436662T3 (es) * 2008-02-11 2014-01-03 Wyeth Llc Procedimientos de preparación de la forma polimórfica A de acetato de bazedoxifeno
WO2009102771A1 (en) * 2008-02-11 2009-08-20 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
EP2493477B1 (en) 2009-10-27 2013-10-16 Wyeth LLC Bazedoxifene formulations with antioxidants
US8154175B2 (en) * 2009-12-16 2012-04-10 Hamilton Sundstrand Corporation Sensing device
WO2012007453A1 (en) 2010-07-14 2012-01-19 Sandoz Ag Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
EP2616463A4 (en) * 2010-09-14 2014-01-08 Reddys Lab Ltd Dr PREPARATION OF CRYSTALLINE BAZEDOXIFES AND THEIR SALTS
EP2471770A1 (en) 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
US9751835B2 (en) 2013-05-15 2017-09-05 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
CN111060619B (zh) * 2019-12-18 2022-11-18 北京鑫开元医药科技有限公司 一种醋酸巴多昔芬杂质的检测方法
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
PT802183E (pt) 1996-04-19 2002-03-28 American Home Prod Agentes estrogenicos
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
PT1025077E (pt) 1997-10-15 2007-05-31 Wyeth Corp Novas ariloxi-alquil-dialquilaminas
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
RU2005101635A (ru) 2002-06-25 2005-08-10 Уайт (Us) Применение производных тиооксиндола в терапии гормонозависимых состояний
WO2005100316A1 (en) 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of a bazedoxifene acetate

Also Published As

Publication number Publication date
JP2007532560A (ja) 2007-11-15
KR20060135866A (ko) 2006-12-29
IL178236A0 (en) 2006-12-31
PE20060676A1 (es) 2006-07-24
EP1732890A1 (en) 2006-12-20
PA8629101A1 (es) 2005-11-25
US20050227965A1 (en) 2005-10-13
ECSP066911A (es) 2006-12-20
WO2005100316A1 (en) 2005-10-27
TWI346105B (en) 2011-08-01
AU2005233133A1 (en) 2005-10-27
RU2006132180A (ru) 2008-05-20
CR8615A (es) 2007-06-06
US7683051B2 (en) 2010-03-23
JP2009035535A (ja) 2009-02-19
AR048527A1 (es) 2006-05-03
CA2561010A1 (en) 2005-10-27
BRPI0509191A (pt) 2007-09-25
TW200606149A (en) 2006-02-16
SG151331A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
NO20065052L (no) Krystallinsk polymorf av et bazedoksifenacetat
NO20065046L (no) Krystallinsk polymorf av bazedoksifenacetat
NO20090295L (no) Substituerte heteroarylderivater
NO2012017I1 (no) Benzimidazolderivat, fremgangsmåte for fremstilling derav, medikament inneholdende denne forbindelsen samt anvendelse av forbindelsen.
NO20076067L (no) Metoder for syntese av substituerte 3-cyanokinoliner og mellomprodukter av denne
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
NO20081926L (no) Oppslemmingsblanding og fremgangsmåter for fremstilling av denne
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
EA201790678A1 (ru) Бициклические гетероарильные соединения
NO20093060L (no) Spirosykliske sykloheksanderivater
NO20080784L (no) Histondeacetylaseinhibitorer
NO20071078L (no) Antivirale forbindelser
NO20070866L (no) Antivirale forbindelser.
NO20082395L (no) Krystallinske former av 1'-(1-metyl)-4'-[(2-fluor-4-metoksyfenyl)metyl]-5'-metyl-1H-pyrazol-3'-O-beta-D-glucopyranosid, en fremstillingsmetode og anvendelse av denne for fremstilling av medikamenter
MY151036A (en) Synthesis of (r)-n-methylnaltrexone
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
EA201170703A1 (ru) Производные адамантилбензамида
ATE497492T1 (de) Reinigung von montelukast
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
NO20080412L (no) Ny fysiologisk forbindelse Nesfatin, forbindelse relevant dertil og anvendelse av forbindelsene
NO20054762L (no) Polymorphs of aripiprazole
TW200738281A (en) Bazedoxifene acetate formulations
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
EA200801414A1 (ru) Кальцилитические соединения

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application